Lisa M. Ferri is a partner in Mayer Brown’s New York office and co-leader of the firm’s global Intellectual Property practice. She serves as lead trial and appellate counsel for high‐profile companies in the pharmaceutical, biotechnology, and medical device industries.
Lisa is a seasoned and versatile litigator, having tried high-stakes cases in federal courts across the country and the International Trade Commission, and argued before the Patent Trial and Appeal Board (PTAB) and the Federal Circuit Court of Appeals. She has significant expertise guiding companies through patent challenges under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA).
Lisa’s life sciences practice spans a broad range of therapeutic areas and technologies—from pharmaceuticals and biologics for the treatment of HIV/AIDS, cancer, hepatitis, influenza, auto-immunities, anemia, emesis, and BPH, to drug delivery systems, research tools, recombinant DNA, RNAi and a variety of medical devices.
Her pharmaceutical practice focuses on representing innovator companies in cases brought pursuant to the Hatch-Waxman Act. She has successfully defended a number of key blockbuster drugs. Following enactment of the America Invents Act, Lisa handled one of the first co-pending inter partes reviews and district court litigations relating to the Orange Book listed drug Lexiva®—the first “lead compound” IPR to come before the PTAB. Lisa also concentrates on patent litigation dealing with large molecule biologics, including a series of antibody litigations involving the well-known “Cabilly” patent portfolio.
Lisa is an adjunct professor at Fordham University School of Law, where she teaches Patent Litigation. Lisa serves as co-chair of the firm’s global Women’s Leadership Committee.
- Seton Hall University Law School, JD
- University of Virginia, BA
- New York
- New Jersey
- US District Court for the District of New Jersey
- US District Court for the Southern District of New York
- US District Court for the Eastern District of New York
- US Court of Appeals for the Federal Circuit
- US Court of International Trade
- Member of the American Bar Association, Litigation and Intellectual Property Law sections
- Member of the New York State Bar Association, Intellectual Property Law section
- Intellectual Property Owners Association, Litigation Committee, NYIPLA and AIPLA
- Member American Intellectual Property Law Association
- Board Member, Women in Law Empowerment Forum (WILEF)
- Lead counsel in biotech patent infringement suit involving PD-1/PD-L1 immunotherapy technology (Bristol-Myers Squibb, Ono Pharmaceutical and Tasuku Honjo v. EMD Serono, Merck KGaA and Pfizer, D. Del.)
- Lead counsel in patent infringement suit involving antibody drug Lemtrada® for the treatment of multiple sclerosis (Genzyme v. Genentech and City of Hope, C.D. Cal.) as well as related Inter Partes Review before the US Patent and Trademark Office (Genzyme v. Genentech and City of Hope, USPTO)
- Lead counsel in biotech patent infringement suit involving antibody therapies Erbitux® and Yervoy® (Bristol‐Myers Squibb v. Genentech and City of Hope, C.D. Cal.)
- Lead counsel in life sciences patent and trademark litigation for IP holder relating to medical devices (Zest IP Holdings LLC et al. v. Implant Direct et al.; S.D. Cal.)
- Represented pharma-biotechnology company in patent litigation involving transdermal drug delivery product (Elan Corp. v. Cygnus Therapeutics, N.D. Cal.)
- Representation of cash management and mutual fund corporation in trademark infringement suit (Reserve Management Corp. v. Reserve Inc., S.D.N.Y.).
Rate : $$$